A novel apoferritin nanocage with ecm promoting, ferroptosis suppressing and inflammation targeting property for osteoarthritis therapy
Notably, the age-related increases in nitration of ECM-bound HGF were predominant on fast IIa and IIx myofibers 32 , corresponding with the fast fiber-preference observed in age-related muscle atrophy and impaired regeneration in humans in which fast IIb fibers are scarce 33,34,35, 39
PRP therapy , on the other hand, is often recommended for milder cases of joint pain or early-stage arthritis
Manufacturers and prescribers should be aware that BPC-157 is not approved by the FDA for any human use, was listed as Category 2 on the FDAs bulk substances list (substances that may present significant safety risks), and is prohibited by the World Anti-Doping Agency (WADA) under the S0: Non-Approved Substances category
Published online May 16, 2024